Matthew Bonaparte

2.9k total citations
38 papers, 1.4k citations indexed

About

Matthew Bonaparte is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Epidemiology. According to data from OpenAlex, Matthew Bonaparte has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Public Health, Environmental and Occupational Health, 27 papers in Infectious Diseases and 5 papers in Epidemiology. Recurrent topics in Matthew Bonaparte's work include Mosquito-borne diseases and control (28 papers), Viral Infections and Vectors (24 papers) and Malaria Research and Control (14 papers). Matthew Bonaparte is often cited by papers focused on Mosquito-borne diseases and control (28 papers), Viral Infections and Vectors (24 papers) and Malaria Research and Control (14 papers). Matthew Bonaparte collaborates with scholars based in United States, France and Mexico. Matthew Bonaparte's co-authors include Edward Barker, Jeffrey P. Ward, Christopher C. Broder, Gary Crameri, Bruce A. Mungall, Vidita Choudhry, Dimiter S. Dimitrov, Bryan T. Eaton, Antony S. Dimitrov and Katharine N. Bossart and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Matthew Bonaparte

36 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Bonaparte United States	17	687	589	421	407	289	38	1.4k
Milind M. Gore India	17	707 1.0×	668 1.1×	461 1.1×	170 0.4×	339 1.2×	44	1.3k
Penelope Koraka Netherlands	20	1.3k 1.9×	1.4k 2.3×	191 0.5×	117 0.3×	224 0.8×	40	1.8k
Katherine L. Williams United States	17	1.5k 2.2×	1.6k 2.7×	257 0.6×	274 0.7×	284 1.0×	23	2.1k
Sébastien Plumet France	14	600 0.9×	527 0.9×	263 0.6×	183 0.4×	39 0.1×	19	1.0k
Mathilde Guerbois United States	15	562 0.8×	594 1.0×	236 0.6×	97 0.2×	66 0.2×	17	898
Mary Kate Hart United States	25	1.4k 2.1×	414 0.7×	739 1.8×	324 0.8×	188 0.7×	40	2.1k
Carlos A. Sariol Puerto Rico	17	740 1.1×	667 1.1×	190 0.5×	129 0.3×	111 0.4×	47	1.0k
Mat Yamage Bangladesh	21	242 0.4×	229 0.4×	558 1.3×	209 0.5×	124 0.4×	32	1.2k
Anneke Funk Germany	16	699 1.0×	727 1.2×	407 1.0×	226 0.6×	132 0.5×	19	1.5k
Xishan Lu China	13	690 1.0×	598 1.0×	623 1.5×	149 0.4×	43 0.1×	16	1.2k

Countries citing papers authored by Matthew Bonaparte

Since Specialization

Citations

This map shows the geographic impact of Matthew Bonaparte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Bonaparte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Bonaparte more than expected).

Fields of papers citing papers by Matthew Bonaparte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Bonaparte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Bonaparte. The network helps show where Matthew Bonaparte may publish in the future.

Co-authorship network of co-authors of Matthew Bonaparte

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Bonaparte. A scholar is included among the top collaborators of Matthew Bonaparte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Bonaparte. Matthew Bonaparte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Planas, Delphine, Lin Peng, Lingyi Zheng, et al.. (2024). Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants. Heliyon. 10(5). e27033–e27033.

Namazova-Baranova, Leyla S., В. В. Романенко, A.N. Galustyan, et al.. (2023). Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study. SHILAP Revista de lepidopterología. 21(6). 65–81.

Park, Juliana, Eduardo López‐Medina, María Rosario Capeding, et al.. (2022). Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study. The Lancet Infectious Diseases. 22(6). 901–911. 4 indexed citations

Savarino, Stephen J., Matthew Bonaparte, Hao Wang, et al.. (2022). Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials. The Lancet Microbe. 3(6). e427–e434. 9 indexed citations

Gallichotte, Emily N., Usha K. Nivarthi, Trevor Scobey, et al.. (2022). Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity. Cell Reports. 39(10). 110930–110930. 7 indexed citations

Dhingra, Mandeep Singh, Leyla S. Namazova-Baranova, José Luis Arredondo-Garcı́a, et al.. (2021). Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiology and Infection. 149. e90–e90. 10 indexed citations

Park, Juliana, Sophia Archuleta, Lynette Pei‐Chi Shek, et al.. (2021). Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial. Human Vaccines & Immunotherapeutics. 17(7). 2107–2116. 4 indexed citations

Bonaparte, Matthew, et al.. (2021). Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. Journal of Clinical Investigation. 131(13). 29 indexed citations

DiazGranados, Carlos A., Matthew Bonaparte, Hao Wang, et al.. (2020). Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. The Lancet Infectious Diseases. 21(4). 529–536. 19 indexed citations

10.

Carpp, Lindsay N., Youyi Fong, Matthew Bonaparte, et al.. (2020). Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLoS ONE. 15(6). e0234236–e0234236. 9 indexed citations

11.

Bonaparte, Matthew, James W. Huleatt, Lingyi Zheng, et al.. (2019). Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening. Diagnostic Microbiology and Infectious Disease. 96(3). 114918–114918. 15 indexed citations

12.

Rabaa, Maia A., Yves Girerd-Chambaz, Kien Duong Thi Hue, et al.. (2017). Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. eLife. 6. 37 indexed citations

13.

Harenberg, Anke, Matthew Bonaparte, Florence Boudet, et al.. (2016). Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. PLoS neglected tropical diseases. 10(7). e0004830–e0004830. 15 indexed citations

14.

Swanstrom, Jesica, Anthony M. Byers, Janice M. Moser, et al.. (2016). Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals. The Journal of Infectious Diseases. 215(3). jiw576–jiw576. 98 indexed citations

15.

Timiryasova, Tatyana M., et al.. (2013). Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development. American Journal of Tropical Medicine and Hygiene. 88(5). 962–970. 92 indexed citations

16.

Ward, Jeffrey P., et al.. (2007). HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 110(4). 1207–1214. 152 indexed citations

17.

Bonaparte, Matthew, Antony S. Dimitrov, Katharine N. Bossart, et al.. (2005). Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proceedings of the National Academy of Sciences. 102(30). 10652–10657. 357 indexed citations

18.

Bonaparte, Matthew & Edward Barker. (2004). Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood. 104(7). 2087–2094. 120 indexed citations

19.

Ward, Jeffrey P., Matthew Bonaparte, & Edward Barker. (2004). HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS. 18(13). 1769–1779. 55 indexed citations

20.

Bonaparte, Matthew & Edward Barker. (2003). Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS. 17(4). 487–494. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact